Literature DB >> 22013230

The mouse interleukin (Il)33 gene is expressed in a cell type- and stimulus-dependent manner from two alternative promoters.

Dominique Talabot-Ayer1, Nicolas Calo, Solenne Vigne, Céline Lamacchia, Cem Gabay, Gaby Palmer.   

Abstract

GenBank entries for mouse Il33 reveal the existence of two transcripts, Il33a and Il33b, with different 5'UTRs but coding for the same protein. We investigated expression of these transcripts in different mouse organs and cell types in basal and inflammatory conditions. Il33a and Il33b mRNAs start with different noncoding first exons, transcribed from different promoter regions, which both contain a consensus TATA-like sequence. Constitutive Il33a mRNA expression was detected in mouse stomach, lung, spleen, and brain, whereas basal Il33b mRNA expression was observed only in the stomach. Expression of both transcripts increased after systemic LPS administration. In vitro, we observed high constitutive expression of Il33 transcripts in MEFs. Constitutive Il33a mRNA expression was observed also in BMDCs, where it was preferentially increased in response to poly(I:C), whereas LPS increased levels of Il33a and Il33b mRNA. In contrast, BMMs and Raw 264.7 cells did not express Il33 mRNA constitutively, and LPS stimulation selectively induced expression of Il33b mRNA in these cells. Our data indicate that the Il33 gene is expressed from two alternative promoters in the mouse and that the relative expression of Il33a and Il33b transcripts is cell type- and stimulus-dependent.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22013230     DOI: 10.1189/jlb.0811425

Source DB:  PubMed          Journal:  J Leukoc Biol        ISSN: 0741-5400            Impact factor:   4.962


  27 in total

1.  A carbon nanotube toxicity paradigm driven by mast cells and the IL-₃₃/ST₂ axis.

Authors:  Pranita Katwa; Xiaojia Wang; Rakhee N Urankar; Ramakrishna Podila; Susana C Hilderbrand; Robert B Fick; Apparao M Rao; Pu Chun Ke; Christopher J Wingard; Jared M Brown
Journal:  Small       Date:  2012-07-06       Impact factor: 13.281

Review 2.  Implications for Interleukin-33 in solid organ transplantation.

Authors:  Quan Liu; Hēth R Turnquist
Journal:  Cytokine       Date:  2013-03-27       Impact factor: 3.861

Review 3.  Emerging role of interleukin-33 in autoimmune diseases.

Authors:  Cheng Pei; Mark Barbour; Karen J Fairlie-Clarke; Debbie Allan; Rong Mu; Hui-Rong Jiang
Journal:  Immunology       Date:  2014-01       Impact factor: 7.397

Review 4.  Interleukin 33 is a guardian of barriers and a local alarmin.

Authors:  Nikolas T Martin; Michael U Martin
Journal:  Nat Immunol       Date:  2016-02       Impact factor: 25.606

Review 5.  Interleukin-33 in health and disease.

Authors:  Foo Yew Liew; Jean-Philippe Girard; Heth Roderick Turnquist
Journal:  Nat Rev Immunol       Date:  2016-09-19       Impact factor: 53.106

Review 6.  IL-33: biological properties, functions, and roles in airway disease.

Authors:  Li Yin Drake; Hirohito Kita
Journal:  Immunol Rev       Date:  2017-07       Impact factor: 12.988

7.  Transcriptional regulation of murine IL-33 by TLR and non-TLR agonists.

Authors:  Swamy Kumar Polumuri; Gift Gunaraj Jayakar; Kari Ann Shirey; Zachary J Roberts; Darren J Perkins; Paula M Pitha; Stefanie N Vogel
Journal:  J Immunol       Date:  2012-05-25       Impact factor: 5.422

8.  Stromal cells maintain immune cell homeostasis in adipose tissue via production of interleukin-33.

Authors:  T Mahlakõiv; A-L Flamar; L K Johnston; S Moriyama; G G Putzel; P J Bryce; D Artis
Journal:  Sci Immunol       Date:  2019-05-03

9.  Inducible IL-33 expression by mast cells is regulated by a calcium-dependent pathway.

Authors:  Chia-Lin Hsu; Paul J Bryce
Journal:  J Immunol       Date:  2012-08-24       Impact factor: 5.422

10.  IL-33 is an unconventional Alarmin that stimulates IL-2 secretion by dendritic cells to selectively expand IL-33R/ST2+ regulatory T cells.

Authors:  Benjamin M Matta; Jeremy M Lott; Lisa R Mathews; Quan Liu; Brian R Rosborough; Bruce R Blazar; Hēth R Turnquist
Journal:  J Immunol       Date:  2014-09-12       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.